Document is current
Any future updates will be listed below
-
Authors
Goldscheitter, Galen M.
Seneshaw, Mulugeta
Mirshahi, Faridoddin
Buettmann, Evan G.
Genetos, Damian C.
Sanyal, Arun J.
Donahue, Henry J.
-
Funding
Funding for this research was provided by:
NIH (K99 AR082989, R01 AR073772, P01 CA275740)
- License Information
-
More Information
Article History
Received: 26 November 2024
Accepted: 23 June 2025
First Online: 2 July 2025
Declarations
:
: AJS owns stock or equity in Durect, Genfit, Sanyal Bio, and Tiziana. He receives research support from AstraZeneca, Avant Sante, Boehringer Ingelheim, Bristol Meyers, Intercept, Lilly, Madrigal, Novartis, Novo Nordisk, and Pfizer. He serves as a consultant to 89 Bio, Alnylam, AstraZeneca, BiocellVia, Boehringer Ingelheim, Fibronest, Fractyl, Genentech, GlaxoSmithKline, HistoIndex, Intercept, Madrigal, Merck, NGM Bio, NorthSea, Novartis, Novo Nordisk, PathAI, Pfizer, Regeneron, Roche, Takeda, Target PharmaSolutions, and Terns. The remaining authors declare no competing interests.
